Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom prospective diabetes study (UKPDS) 79

Circulation

Volumn 127, Issue 9, 2013, Pages 980-987

  Davis, Timothy M E ^a   Coleman, Ruth L ^b   Holman, Rury R ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cardiovascular diseases; diabetes mellitus, type 2; myocardial infarction; risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIURETIC AGENT; INSULIN; SULFONYLUREA;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; SEDENTARY LIFESTYLE; SILENT MYOCARDIAL INFARCTION;

ADULT; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84874619596     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.000908     Document Type: Article

References (31)

1. Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ; ADA. Screening for coronary artery disease in patients with diabetes. Diabetes Care. 2007;30:2729-2736.
2. Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction: an update on the Framingham study. N Engl J Med. 1984;311:1144-1147.
3. Medalie JH, Goldbourt U. Unrecognized myocardial infarction: five-year incidence, mortality, and risk factors. Ann Intern Med. 1976;84:526-531.
4. Nadelmann J, Frishman WH, Ooi WL, Tepper D, Greenberg S, Guzik H, Lazar EJ, Heiman M, Aronson M. Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: the Bronx Aging Study. Am J Cardiol. 1990;66:533-537.
5. Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N. Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris: the Reykjavik Study. Ann Intern Med. 1995;122:96-102.
6. Yano K, MacLean CJ. The incidence and prognosis of unrecognized myocardial infarction in the Honolulu, Hawaii, Heart Program. Arch Intern Med. 1989;149:1528-1532.
7. Burgess DC, Hunt D, Li L, Zannino D, Williamson E, Davis TM, Laakso M, Kesäniemi YA, Zhang J, Sy RW, Lehto S, Mann S, Keech AC. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J. 2010;31:92-99.
8. Davis TM, Fortun P, Mulder J, Davis WA, Bruce DG; Fremantle Diabetes Study. Silent myocardial infarction and its prognosis in a communitybased cohort of type 2 diabetic patients: the Fremantle Diabetes Study. Diabetologia. 2004;47:395-399.
9. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study (UKPDS), VIII: study design, progress and performance. Diabetologia. 1991;34:877-890.
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
11. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
12. Elgrishi I, Ducimetiere P, Richard JL. Reproducibility of analysis of the electrocardiogram in epidemiology using the "Minnesota code." Br J Prev Soc Med. 1970;24:197-200.
13. Fahy GJ, Pinski SL, Miller DP, McCabe N, Pye C, Walsh MJ, Robinson K. Natural history of isolated bundle branch block. Am J Cardiol. 1996;77:1185-1190.
14. Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS Risk Engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci. 2001;101:671-679.
15. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172.
16. Scheidt-Nave C, Barrett-Connor E, Wingard DL. Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population. Circulation. 1990;81:899-906.
17. Kannel WB, Dannenberg AL, Abbott RD. Unrecognized myocardial infarction and hypertension: the Framingham study. Am Heart J. 1985;109(pt 1):581-585.
18. Rosenman RH, Friedman M, Jenkins CD, Straus R, Wurm M, Kositchek R. Clinically unrecognized myocardial infarction in the Western Collaborative Group Study. Am J Cardiol. 1967;19:776-782.
19. Targher G, Bertolini L, Zenari L, Lippi G, Pichiri I, Zoppini G, Muggeo M, Arcaro G. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabet Med. 2008;25:45-50.
20. Nicod P, Gilpin E, Dittrich H, Polikar R, Hjalmarson A, Blacky AR, Henning H, Ross J Jr. Short-and long-term clinical outcome after Q wave and non-Q wave myocardial infarction in a large patient population. Circulation. 1989;79:528-536.
21. MacDonald MR, Petrie MC, Home PD, Komajda M, Jones NP, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, McMurray JJ. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care. 2011;34:1394-1396.
22. Mastouri R, Sawada SG, Mahenthiran J. Current noninvasive imaging techniques for detection of coronary artery disease. Expert Rev Cardiovasc Ther. 2010;8:77-91.
23. Dolci A, Panteghini M. The exciting story of cardiac biomarkers: from retrospective detection to gold diagnostic standard for acute myocardial infarction and more. Clin Chim Acta. 2006;369:179-187.
24. Grech ED. ABC of interventional cardiology: percutaneous coronary intervention, I: history and development. BMJ. 2003;326:1080-1082.
25. Al-Mohammad A, Norton MY, Mahy IR, Patel JC, Welch AE, Mikecz P, Walton S. Can the surface electrocardiogram be used to predict myocardial viability? Heart. 1999;82:663-667.
26. Asch FM, Shah S, Rattin C, Swaminathan S, Fuisz A, Lindsay J. Lack of sensitivity of the electrocardiogram for detection of old myocardial infarction: a cardiac magnetic resonance imaging study. Am Heart J. 2006;152:742-748.
27. Sandler LL, Pinnow EE, Lindsay J. The accuracy of electrocardiographic Q waves for the detection of prior myocardial infarction as assessed by a novel standard of reference. Clin Cardiol. 2004;27:97-100.
28. Kondola S, Davis WA, Dembo LG, Davis TM. A cardiac magnetic resonance imaging study of electrocardiographic Q waves in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract. 2008;82:87-92.
29. Marcus EB, Yano K, MacLean CJ. Regression of Q waves following acute myocardial infarction. Am J Epidemiol. 1989;129:105-111.
30. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21-29.
31. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818-828.